Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Multiple administration of omeprazole Single administration of AB-106 · 1 trial · 1 indication
plasma drug peak concentration
area under the plasma drug concentration time curve from 0 to the last measurable drug concentration time point
Area under the plasma drug concentration time curve from 0 to infinity (if it can be calculated reliably)
| Arm | Type | Description |
|---|---|---|
| Omeprazole combined with AB-106 group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Multiple administration of omeprazole Single administration of AB-106 | DRUG | Take AB-106 capsule 400 mg orally on an empty stomach in the morning of the first day of the first cycle Take omeprazole magnesium enteric coated tablets 40mg once a day, 30 minutes before breakfast on days 1-4 of the second cycle. On the morning of the fifth day of the second cycle, the subjects will take omeprazole magnesium enteric coated tablets 40 mg, and AB-106 capsules 400 mg after an interval of 1 hour |
Inclusion Criteria: 1. Chinese male healthy subjects (health refers to the state without clinically relevant abnormalities confirmed by medical history, physical examination, vital signs, 12 lead ECG and clinical laboratory examination). 2. The age at the time of signing the informed consent was be...
AB-106 is an investigational small molecule developed by Nuvation Bio Inc. (ticker NUVB). It has been studied in a Phase 1 pharmacokinetic trial in healthy male volunteers in China. The trial evaluated how omeprazole affects the pharmacokinetics of AB-106.
AB-106 is being developed by Nuvation Bio Inc., which trades under the ticker NUVB. The company sponsored the Phase 1 pharmacokinetic study of AB-106 conducted in China.
AB-106 is in Phase 1 clinical development. One Phase 1 pharmacokinetic trial has been completed, and no active trials are currently listed. The study enrolled 24 healthy male volunteers.
AB-106 has been evaluated in one completed Phase 1 trial, NCT05609929, titled Study the Effect of Omeprazole on AB-106 Pharmacokinetics. The trial enrolled 24 healthy male volunteers in China and was an uncontrolled, non-randomized pharmacokinetic study.
AB-106 is an investigational drug and no therapeutic indication has been disclosed. Its only recorded clinical study was a Phase 1 pharmacokinetic trial examining the effect of omeprazole on AB-106 in healthy volunteers, not a study in patients with a specific disease.
The completed Phase 1 trial NCT05609929 was designed to study the effect of omeprazole on the pharmacokinetics of AB-106. The study enrolled 24 healthy male volunteers in China and has been completed, evaluating drug interaction between the two agents.